You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

CLINICAL TRIALS PROFILE FOR NIZATIDINE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Nizatidine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00373334 ↗ Safety and Efficacy Study of Axid Use in Infants Suffering From Gastroesophageal Reflux Disease (GERD) Completed Braintree Laboratories Phase 3 2006-08-01 The objective of this study is to evaluate the efficacy, acceptability, and safety of Axid Oral Solution versus placebo in the treatment of gastroesophageal reflux disease (GERD) in infants age 30 days up to 1 year.
NCT00486005 ↗ Weight Gain Management in Patients With Schizophrenia Completed Eli Lilly and Company Phase 4 2003-02-01 Evaluate the efficacy of nizatidine in reducing/limiting weight gain in patients with schizophrenia who have been under treatment with olanzapine for at least two months and evaluate the treatment effects on the Eating Inventory, BPRS, number of treatment, emergent adverse events, changes in vital signs, laboratory results and extrapyramidal effects.
NCT01161927 ↗ Bioequivalence Study of Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited Under Non- Fasting Conditions Completed Dr. Reddy's Laboratories Limited Phase 1 2004-07-01 The purpose of this study is to compare experimental evaluation of relative bioavailabilities in healthy, human subjects under non-fasting conditions.
NCT01161940 ↗ Bioequivalence Study of Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited Under Fasting Conditions Completed Dr. Reddy's Laboratories Limited Phase 1 2004-07-01 This is a bioequivalence study of nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited under fasting conditions
NCT01409395 ↗ Drug-Drug Interaction Study With Metformin and Nizatidine Completed National Institute of General Medical Sciences (NIGMS) Phase 1 2011-09-01 This study will address the following question: Does nizatidine affect the pharmacokinetics of metformin in healthy volunteers? Recent studies in the Giacomini laboratory have indicated that nizatidine may block metformin elimination from the kidney by inhibiting organic cation transporter efflux of metformin. The investigators hypothesize that the co-administration of metformin and nizatidine will reduce the renal clearance (CLR) of metformin leading to increased plasma concentrations and potential risk for toxicities. Knowledge of the pharmacokinetic interaction profile of metformin with organic transporter inhibitors, such as nizatidine, is important to help develop safer more effective drug therapy with reduced side effects.
NCT01409395 ↗ Drug-Drug Interaction Study With Metformin and Nizatidine Completed University of California, San Francisco Phase 1 2011-09-01 This study will address the following question: Does nizatidine affect the pharmacokinetics of metformin in healthy volunteers? Recent studies in the Giacomini laboratory have indicated that nizatidine may block metformin elimination from the kidney by inhibiting organic cation transporter efflux of metformin. The investigators hypothesize that the co-administration of metformin and nizatidine will reduce the renal clearance (CLR) of metformin leading to increased plasma concentrations and potential risk for toxicities. Knowledge of the pharmacokinetic interaction profile of metformin with organic transporter inhibitors, such as nizatidine, is important to help develop safer more effective drug therapy with reduced side effects.
NCT02232308 ↗ Modulation of Heme Oxygenase 1 by Nizatidine and Lisinopril in Healthy Subjects Completed National Center for Research Resources (NCRR) Phase 1 2014-07-01 To assess if oral nizatidine or lisinopril alone and in combination will increase heme oxygenase 1 (HO-1) protein concentration and activity compared to placebo in healthy subjects.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Nizatidine

Condition Name

Condition Name for Nizatidine
Intervention Trials
Healthy 3
Heartburn 1
Pulmonary Aspiration of Gastric Contents 1
Schizophrenia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Nizatidine
Intervention Trials
Gastroesophageal Reflux 2
Esophagitis, Peptic 1
Pneumonia 1
Gastroparesis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Nizatidine

Trials by Country

Trials by Country for Nizatidine
Location Trials
United States 16
Canada 1
Brazil 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Nizatidine
Location Trials
California 2
Arkansas 1
Minnesota 1
Utah 1
Texas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Nizatidine

Clinical Trial Phase

Clinical Trial Phase for Nizatidine
Clinical Trial Phase Trials
Phase 4 3
Phase 3 1
Phase 1 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Nizatidine
Clinical Trial Phase Trials
Completed 8
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Nizatidine

Sponsor Name

Sponsor Name for Nizatidine
Sponsor Trials
Dr. Reddy's Laboratories Limited 2
Braintree Laboratories 1
King Saud University 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Nizatidine
Sponsor Trials
Other 6
Industry 5
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.